WO2004087199A1 - インスリン抵抗性改善用組成物 - Google Patents
インスリン抵抗性改善用組成物 Download PDFInfo
- Publication number
- WO2004087199A1 WO2004087199A1 PCT/JP2004/004497 JP2004004497W WO2004087199A1 WO 2004087199 A1 WO2004087199 A1 WO 2004087199A1 JP 2004004497 W JP2004004497 W JP 2004004497W WO 2004087199 A1 WO2004087199 A1 WO 2004087199A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- conglycinin
- protein
- composition
- insulin resistance
- soybean
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 54
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title claims abstract description 36
- 206010022489 Insulin Resistance Diseases 0.000 title claims abstract description 32
- 108700037728 Glycine max beta-conglycinin Proteins 0.000 claims abstract description 39
- 239000003814 drug Substances 0.000 claims abstract description 9
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 46
- 108090000623 proteins and genes Proteins 0.000 claims description 46
- 235000010469 Glycine max Nutrition 0.000 claims description 33
- 244000068988 Glycine max Species 0.000 claims description 28
- 235000013305 food Nutrition 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 21
- 208000011580 syndromic disease Diseases 0.000 claims description 15
- 235000019750 Crude protein Nutrition 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 9
- 206010003210 Arteriosclerosis Diseases 0.000 abstract description 6
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 4
- 235000018102 proteins Nutrition 0.000 description 42
- 238000012360 testing method Methods 0.000 description 27
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 19
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 16
- 239000008280 blood Substances 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 239000000902 placebo Substances 0.000 description 13
- 229940068196 placebo Drugs 0.000 description 13
- 102000004877 Insulin Human genes 0.000 description 8
- 108090001061 Insulin Proteins 0.000 description 8
- 230000037406 food intake Effects 0.000 description 8
- 229940125396 insulin Drugs 0.000 description 8
- 235000012054 meals Nutrition 0.000 description 8
- 108010011619 6-Phytase Proteins 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 229940085127 phytase Drugs 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 235000002949 phytic acid Nutrition 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 229940068041 phytic acid Drugs 0.000 description 5
- 239000000467 phytic acid Substances 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108010073771 Soybean Proteins Proteins 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- 108010083391 glycinin Proteins 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 2
- 102000011632 Caseins Human genes 0.000 description 2
- 108010076119 Caseins Proteins 0.000 description 2
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 2
- 206010020710 Hyperphagia Diseases 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 102000014171 Milk Proteins Human genes 0.000 description 2
- 108010011756 Milk Proteins Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 229940123464 Thiazolidinedione Drugs 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 235000021239 milk protein Nutrition 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 235000020830 overeating Nutrition 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000008085 renal dysfunction Effects 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 235000019710 soybean protein Nutrition 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 101000767750 Carya illinoinensis Vicilin Car i 2.0101 Proteins 0.000 description 1
- 101000767759 Corylus avellana Vicilin Cor a 11.0101 Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 101000622316 Juglans regia Vicilin Jug r 2.0101 Proteins 0.000 description 1
- 238000007696 Kjeldahl method Methods 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 101000767757 Pinus koraiensis Vicilin Pin k 2.0101 Proteins 0.000 description 1
- 101000767758 Pistacia vera Vicilin Pis v 3.0101 Proteins 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 102000034238 globular proteins Human genes 0.000 description 1
- 108091005896 globular proteins Proteins 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000019685 rice crackers Nutrition 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000021195 test diet Nutrition 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- composition for improving insulin resistance Composition for improving insulin resistance
- the present invention relates to a composition for improving insulin resistance.
- heart disease and cerebral tubule 1 disease together make up the leading cause of death by overcoming malignant neoplasms (cancer).
- cancer malignant neoplasms
- the cause of these diseases is atherosclerosis, which is based on lifestyle-related diseases such as diabetes, hypertension, hyperlipidemia, and obesity.
- lifestyle-related diseases are largely caused by environmental factors such as overeating of eating habits, high fat and high calorie, lack of exercise, and irregularities in daily life accompanying the development of the postwar Japanese economy.
- These lifestyle-related diseases alone can lead to arteriosclerosis, but in practice, multiple cases often result in arteriosclerosis.
- Syndrome X for example, Reaven G, Curr Treat Options Cardiovasc Med. Aug; 3 ( 4): See 323-332, 2001.
- the trigger for Syndrome X is said to be insulin resistance (insulin dysfunction).
- Insulin resistance is a phenomenon in which the action of insulin decreases due to a decrease in insulin sensitivity in muscle, liver, and adipose tissues, which are the targets of insulin. Insulin is a hormone secreted by knee beta cells to lower blood sugar, but if this hypersecretion continues for a long time, the resistance of target cells increases, and the knee beta cells become fatigued and insulin secretion deficiency occurs. It leads to the development of type II diabetes.
- Insulin resistance involves genetic factors, obesity, overeating, lack of exercise, stress, pregnancy, aging, and environmental factors such as long-term use of steroids. It is desirable to improve these factors to improve insulin resistance, and diet and exercise are effective in conserving endogenous insulin. If the effect is insufficient, use a thiazolidinedione agent or (b) a biguanide agent as a drug therapy to improve insulin resistance. Administer. However, these drugs have side effects and must be used with strict restrictions on their use. In particular, (a) thiazolidinedione is contraindicated in patients with severe liver damage and renal dysfunction, and side effects have been reported. (B) Biguanides are contraindicated in patients with renal dysfunction and lactic acidosis.
- One of the objects of the present invention is to reduce insulin resistance, thereby preventing arteriosclerosis and preventing type 2 diabetes, and as a food or drink that has no side effects or contraindications like conventional drugs. It is to provide a useful composition.
- Another object of the present invention is to provide a composition useful for the prevention and / or treatment of Syndrome X.
- the present inventors fractionated and purified -conglycinin among soybean proteins, prepared compositions containing the same, and studied various effects on lipid metabolism and glucose metabolism.
- the present inventors have found that such a composition has an excellent effect of regulating blood sugar changes and insulin secretion, and have completed the present invention.
- composition for improving insulin resistance comprising ⁇ -condaricinin as an active ingredient
- composition according to the above (1) which is a food or drink
- composition according to the above (1) which is a medicament
- the [3-conglycinin used is soybean] [3-conglycinin is 40% by weight or more per crude protein)
- composition is a medicament
- (11) a method for improving insulin resistance, which comprises providing an effective amount of ⁇ -conglycin to a mammal in need of insulin resistance improvement,
- composition for the prevention and treatment of X A composition for the prevention and treatment of X,
- composition according to (14), wherein ⁇ -conglycinin is derived from soybean
- composition according to the above-mentioned (14), wherein the [3-conglycinin used] is soybean per crude protein] 8-conglycinin is 40% by weight or more] 3-conglycinin protein,
- Syndrome X prophylaxis A method for preventing and treating syndrome X, which comprises providing a therapeutically effective amount of 3-condaricinin to a mammal in need thereof.
- (21) The method according to the above (20), wherein ⁇ -conglycinin is derived from soybean, and
- the composition of the present invention can prevent arteriosclerosis and prevent type II diabetes by reducing insulin resistance and improve insulin resistance without side effects or contraindications like conventional drugs. It is a composition for prevention and treatment of Syndrome X. BRIEF DESCRIPTION OF THE FIGURES
- FIG. 1 is a graph showing changes in blood glucose in Test Example 1.
- FIG. 2 is a graph showing changes in blood insulin concentration (hereinafter abbreviated as IRI) in Test Example 1.
- FIG. 3 is a graph showing the change of ost—IR (homeostasis model assessment-insul in resistance) in git test sequence 1.
- FIG. 4 is a graph showing HOMA-IR after two weeks of ingestion of a test meal and placebo in Test Example 2.
- Globulin which is a generic term for soluble globular proteins in soybean, includes 2S, 7S, 11S, and 15S, and -conglycinin in the present invention corresponds to 7S. It is also called 7S glopurine, while 11S is called glycinin.
- ⁇ -conglycinin is composed of three types of subunits, ⁇ ; and ⁇ ', and when referring to the amount of 3-conglycinin, it refers to the total amount of these a, a, and subunits.
- ⁇ -conglycinin is prepared by the usual method for producing isolated soybean protein.
- soybean j3-conglycen protein containing at least 40% by weight of ⁇ .-conglycinin per protein is obtained.
- Such proteins per; 3 - The use of conglycinin protein more efficiently] 3 - - Soy J3 containing 4 0 by weight 0/0 or more as conglycinin conglycinin content can be set.
- a wider range of uses can be expected if a method capable of fractionating 3-conglycinin having a purity sufficient for use without using a reducing agent is used.
- an enzyme or enzyme preparation such as phytase / phosphatase having a phytic acid-degrading activity in the obtained fraction containing [3-conglycinin as a main component]
- phytic acid is decomposed and removed to 1.2% by weight or less, preferably 0.2% by weight or less, more preferably 0.1% by weight or less per protein.
- soybean ⁇ -conglycinin protein containing at least 80% by weight of / 3-conglycinin per protein can be obtained, and the j3-conglycinin content can be set more efficiently.
- those prepared from defatted soybeans using phytase in accordance with the method of separating -conglycinin and darishiyun from the defatted soybeans are preferred because they have a high / 3 -conglycinin content (for example, SAITO, Biosci Biotechnol Bioche Vol. 65, No4 Page 884-887, 2001).
- the amount of / 3-conglycinin in the composition of the present invention containing -conglycinin as an active ingredient is not particularly limited, but the amount of ⁇ -conglycinin is small. If it is too low, a large amount must be ingested.
- the amount of [3-conglycine] per composition is from 2 to: L00% by weight, preferably in the range of 5 to 95% by weight. It is compounded by.
- composition of the present invention may optionally contain an excipient, a carrier, a diluent, a surfactant, a sweetener, an acidulant, a flavor, a preservative, an antioxidant, and the like, as necessary.
- composition of the present invention containing [3-conglycinin] can be made into a powdered food, a granule, a solid, a fluid, a liquid or the like in the form of a food or drink or pharmaceutical according to a conventional method.
- the method of ingestion is not particularly limited, such as oral and tube administration.
- the composition of the present invention is preferably a food or drink in view of the required amount of ingestion.
- it can be health foods and the like, and can be general foods and drinks such as rice crackers, bread, baked goods, bakery foods, cheese-like foods, yogurt-like foods, and tofu-like foods.
- ⁇ -conglycinin is very safe because it is fractionated and purified from soybeans. It is necessary to improve insulin resistance and prevent or treat Syndrome X.
- An animal eg, a human, a puppy, a puppy, a pig, a dog, a cat, a mouse, a rat, a puppy, etc.
- -conglycinin ' is given to an adult (body weight 6 O kg) per day from 2 to: L
- the composition in an amount of 0 g or more in 1 to several times a day, and ⁇ -conglycinin. From the viewpoint of safety, the upper limit of intake is not particularly limited.
- the method for evaluating insulin resistance herein conforms to ⁇ -IR used in immunological studies.
- the calculation formula is [Fasting blood glucose level mg / d1 X Fasting IRI ⁇ Ud1 ⁇ 405]. If this value is 2 or more, it is determined that there is insulin resistance. However, the fasting blood glucose level at this time tends to reflect insulin resistance, so it should be measured at 14 O mg or less.
- the main analytical methods in Production Examples and Test Examples are as follows.
- Nitrogen content was determined based on the Kjeldahl method and converted to crude protein by multiplying by a factor of 6.25.
- the migration pattern obtained by the above-mentioned SDS-polyacrylamide electrophoresis was measured as an area using a densitometer, and the area ratio of the relevant fraction to the total area was defined as purity (based on SPE).
- 3-conglycinin content refers to the total amount of ⁇ , ⁇ ',] 3 subunits, and glycinin content refers to the total amount of acidic polypeptides ( ⁇ ) and basic polypeptides ( ⁇ ).
- the purity may be determined by the corrected purity in consideration of the amount of the lipid-associated protein mixed therein, as described below. However, in this specification, the purity is determined according to the S ⁇ II standard. Correction purity
- the band staining of the stained protein was measured, and the purity was shown to be 80%.
- the amount of phytin ⁇ was 1.8% and 0.05%, respectively, per protein, confirming that phytate was almost completely decomposed and removed by phytase treatment.
- the low phytin j8-conglycinin protein had a chromata oil content of 0.8%.
- the total sulfur-containing amino acids cystine and Mechionin at 25 m g g protein it showed a high value as compared to the purification one conglycinin protein which is originally 5 mg / g protein, suggesting that still a lot of impurities.
- the low phytin] 3-conglycinin protein thus obtained was subjected to SDS-polyacrylamide gel electrophoresis, and the purity of the band was determined to be 90 ° / 0 from the measurement of the degree of staining of the stained protein band. It has been shown.
- the phytic acid content was 0.05% per protein, and it was confirmed that phytic acid was almost completely decomposed and removed.
- the product had a chromata oil content of 0.5%, which was significantly lower than that of Production Example 1.
- the sum of the sulfur-containing amino acids of cystine and methionine is 1.2 mg Zg protein, which is originally 5 mg / g protein.Purified soybean ⁇ -conglycinin with much less impurities than conglycinin protein It was suggested that it was a protein.
- Table 1 shows the composition of the] 3-chondaricinin protein used in the present invention. - ⁇ table 1
- Test meal Placebo Soybean ⁇ -conglycinin protein 80% ⁇
- FIG. 1 shows changes in blood glucose
- Fig. 2 shows changes in IRI.
- Placebo increased 1 hour after ingestion of both blood glucose and IRI, whereas the test diet suppressed the increase.
- FIG. 3 shows a diagram using a formula for calculating HOMA-IR (blood glucose mg / d 1 XIR I ⁇ / ⁇ 1 ⁇ 405), which is an indicator of insulin resistance based on blood glucose and I RI.
- the placebo increased one hour after ingestion, whereas the increase was suppressed in the test meal.
- Test Example 2 and placebo composition Ingredients Test meal Placebo Soybean] 3-Conglycinin protein 50%
- A—I R 2 and above are judged to be insulin resistant.
- the placebo was 2 or more compared to 2 or less in the test meal, and insulin resistance was improved.
- ⁇ -conglycinin as an active ingredient, a composition as a food or drink or medicine which improves insulin resistance, is effective for preventing syndrome X, preventing arteriosclerosis, and preventing type II diabetes Things can be provided.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005504236A JPWO2004087199A1 (ja) | 2003-03-31 | 2004-03-30 | インスリン抵抗性改善用組成物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-097302 | 2003-03-31 | ||
JP2003097302 | 2003-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004087199A1 true WO2004087199A1 (ja) | 2004-10-14 |
Family
ID=33127546
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/004497 WO2004087199A1 (ja) | 2003-03-31 | 2004-03-30 | インスリン抵抗性改善用組成物 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPWO2004087199A1 (ja) |
WO (1) | WO2004087199A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007023776A1 (ja) * | 2005-08-23 | 2007-03-01 | Kyoto University | サルモデルで薬効が確認された骨粗鬆症の予防又は治療剤 |
WO2011122389A1 (ja) | 2010-03-31 | 2011-10-06 | 日清オイリオグループ株式会社 | 糖尿病の予防又は治療用油脂組成物 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002026243A1 (fr) * | 2000-09-29 | 2002-04-04 | Fuji Oil Company, Limited | Composition permettant de reduire les graisses neutres dans le sang |
WO2002028198A1 (fr) * | 2000-10-02 | 2002-04-11 | Fuji Oil Company, Limited | Protéine de soja fractionnée et procédé de production |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3726410B2 (ja) * | 1997-03-28 | 2005-12-14 | 不二製油株式会社 | 大豆たん白含有飲料 |
-
2004
- 2004-03-30 JP JP2005504236A patent/JPWO2004087199A1/ja active Pending
- 2004-03-30 WO PCT/JP2004/004497 patent/WO2004087199A1/ja active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002026243A1 (fr) * | 2000-09-29 | 2002-04-04 | Fuji Oil Company, Limited | Composition permettant de reduire les graisses neutres dans le sang |
WO2002028198A1 (fr) * | 2000-10-02 | 2002-04-11 | Fuji Oil Company, Limited | Protéine de soja fractionnée et procédé de production |
Non-Patent Citations (2)
Title |
---|
MAEBUCHI MOTOHIRO ET AL.: "Amino-san o hoju shita daizu 7S globulin shoku ga shishtsu taisha ni oyobosu eikyo", JAPAN SOCIETY FOR BIOSCIENCE, BIOTECHNOLOGY, SOKAI KOEN YOSHISHU, 5 March 2003 (2003-03-05), pages 52, XP002982596 * |
MAEBUCHI MOTOHIRO ET AL.: "Taizu 7S globulin (beta-conglutinin) shoku ni yoru mouse kessei tryglyceride teika sayo to sono mechanism", THE JAPANESE SOCIETY OF NUTRITION AND FOOD SCIENCE SOKAI KOEN YOSHISHU, 2002, pages 250, XP002982595 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007023776A1 (ja) * | 2005-08-23 | 2007-03-01 | Kyoto University | サルモデルで薬効が確認された骨粗鬆症の予防又は治療剤 |
WO2011122389A1 (ja) | 2010-03-31 | 2011-10-06 | 日清オイリオグループ株式会社 | 糖尿病の予防又は治療用油脂組成物 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2004087199A1 (ja) | 2006-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gilani et al. | Effects of antinutritional factors on protein digestibility and amino acid availability in foods | |
CA2624123C (en) | Glucagon-like peptide-1 secretagogue, glucagon-like peptide-1 secretagogue food or drink, inhibitor of postprandial rise in blood glucose, and inhibitory food or drink of postprandial rise in blood glucose | |
JP5715117B2 (ja) | 摂食障害治療剤 | |
JP2021020954A (ja) | 動植物由来ペプチド含有血清カルノシン分解酵素阻害用組成物 | |
WO2011039999A1 (ja) | 脂肪分解促進作用を有する組成物 | |
KR20060082015A (ko) | 난유래 골 강화 조성물 | |
JP4808218B2 (ja) | 抗糖尿病作用を有する蛋白加水分解物 | |
JP3068656B2 (ja) | 新規なペプチド及びアンジオテンシン変換酵素阻害ペプチド並びにそれらを含有する経口摂食組成物 | |
WO2005092367A1 (ja) | アディポネクチン分泌促進組成物 | |
EP2030629B1 (en) | Alpha-s-casein as lipid-metabolism-improving agent | |
JP4461680B2 (ja) | 血中中性脂肪低減用組成物 | |
Luhovyy et al. | Food proteins in the regulation of blood glucose control | |
WO2004087199A1 (ja) | インスリン抵抗性改善用組成物 | |
JP6083085B2 (ja) | アンジオテンシン変換酵素阻害剤およびその用途 | |
JPWO2006101181A1 (ja) | 肝機能障害予防もしくは改善組成物、及び肝機能障害予防もしくは改善法 | |
JP2012062309A (ja) | 筋肉増加用組成物 | |
US20080124449A1 (en) | Food for Preventing Life Style-Related Diseases | |
Moughan | Digestion and absorption of proteins and peptides | |
Liu et al. | Applications in nutrition: clinical nutrition | |
TW202402190A (zh) | 包含源自乳清蛋白的肽的生長促進用組合物 | |
Takamatsu | Soy peptides As Functional Food Material | |
JPWO2004009107A1 (ja) | 体脂肪低減剤又は体脂肪増加抑制剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005504236 Country of ref document: JP |
|
122 | Ep: pct application non-entry in european phase |